Professor Claudine Bonder OAM is an expert in vascular biology with 25 years experience having trained both in Australia and overseas. She currently heads the Vascular Biology and Cell Trafficking Laboratory at the Centre for Cancer Biology in Adelaide. During her career, Claudine has been awarded the prestigious Early Career Research Award from the Australian Academy of Sciences in 2005, a SA Young Tall Poppy in 2010, was an ASMR Leading Light finalist in 2013, won the Women in Innovation (emerging innovator) in 2016 and in 2025 was awarded a Medal of the Order of Australia.
Research Program Overview:
Blood vessels form an extensive network that transports cells, oxygen and nutrients throughout all tissues and organs. Blood vessels ... Read more
About me
Professor Claudine Bonder OAM is an expert in vascular biology with 25 years experience having trained both in Australia and overseas. She currently heads the Vascular Biology and Cell Trafficking Laboratory at the Centre for Cancer Biology in Adelaide. During her career, Claudine has been awarded the prestigious Early Career Research Award from the Australian Academy of Sciences in 2005, a SA Young Tall Poppy in 2010, was an ASMR Leading Light finalist in 2013, won the Women in Innovation (emerging innovator) in 2016 and in 2025 was awarded a Medal of the Order of Australia.
Research Program Overview:
Blood vessels form an extensive network that transports cells, oxygen and nutrients throughout all tissues and organs. Blood vessels are key components in our fight against disease and improved understanding of endothelial cells (ECs, specialised cells which form the inner lining of blood vessels), will provide new knowledge and novel treatment options for many fatal diseases, including cancer, heart disease and diabetes.
We have world leading research in vasculogenic mimicry (VM), a process wherein cancer cells themselves form vascular-like structures to increase access to the blood supply to assist in tumour growth. In the most aggressive and difficult to treat cancers of the breast, skin and pancreas, increased VM is associated with poor clinical outcome. We have begun to identify novel elements in VM and are now targeting these with an overall aim to provide better outcomes for cancer patients.
Current Research Projects:
About me
Australian Vascular Biology Society (AVBS)
Australasian Society for Immunology (ASI)
North American Vascular Biology Organisation (NAVBO)
American Association of Immunologists (AAI)
Australian Society for Medical Research (ASMR)
Australian and New Zealand Microcirculation Society (ANZMS)
About me
Doctor of Philosophy Flinders University of South Australia
1990-1993 B.Sc. (Hons.), University of Adelaide, SA.
1998-2001 PhD, Flinders University, Adelaide, SA.
2001-2004 Post-doctoral fellow with Dr P Kubes, Calgary, Canada.
2005-2007 Post-doctoral fellow with Prof J Gamble, IMVS, Adelaide, SA.
Our expertise in blood vessels, and the endothelial cells which form their inner lining, allows us to critically interrogate diseases such as cancer, cardiovascular disease and diabetes. Our ultimate aim is to understand the fundamental biology of the blood vasculature so that new treatment opportunities for the most debilitating and deadly diseases can be produced to save thousands of lives every year, worldwide.
Research
Excludes commercial-in-confidence projects.
Advancing a new targeted antibody to combat pancreatic cancer, PanKind Australia - New Treatment Grant, 16/12/2024 - 31/12/2026
CRC-P: Internal Testing and assessment of CAR-T cells using in vitro methods and in vivo animal tumour models, UniSA-Internal, 29/02/2020 - 30/06/2026
Advancing a novel early detection biomarker for pancreatic cancer, Tour de Cure Ltd, 01/03/2022 - 31/12/2025
Enhancing Skin Cancer Diagnosis and Treatment through biomarker discovery, Tour de Cure Ltd, 01/01/2025 - 31/12/2025
Exploiting blood vessels as conduits for the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 02/10/2023 - 31/10/2025
MTA_ATCC - Spatial proteomics to define tumour microenvironments , Unknown, 11/10/2022 - 11/10/2024
Desmoglein-2; an unsuspected regulator of melanoma, NHMRC - Project Grant, 01/01/2019 - 31/12/2022
Investigating a novel adhesion molecule in pancreatic cancer, PanKind Australia - New Treatment Grant, 01/01/2022 - 31/10/2022
Engineered cell and exosome therapy for pulmonary vascular disease, NHMRC - Project Grant, 01/01/2018 - 31/12/2021
Targeting the IL-3/IL-3 receptor axis to prevent breast cancer progression., CA-Priority-driven Collaborative Cancer Research Scheme, 01/05/2016 - 31/03/2020
Desmoglein-2: A novel lifeline to treat diabetes, NHMRC - Project Grant, 01/01/2016 - 31/12/2019
Validation of a novel therapeutic target in multiple myeloma, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2025 |
Open access
|
2024 |
Open access
2
1
2
|
2023 |
Open access
13
15
6
|
2023 |
Open access
4
5
2
|
2022 |
Open access
11
12
13
|
Year | Output |
---|---|
2025 |
Open access
|
2024 |
Open access
2
1
2
|
2024 |
Open access
1
|
2024 |
Open access
3
3
198
|
2024 |
Open access
3
2
4
|
2023 |
Open access
13
15
6
|
2023 |
Open access
8
9
45
|
2023 |
Open access
4
5
2
|
2023 |
Open access
7
6
4
|
2022 |
Open access
16
|
2022 |
1
1
|
2022 |
Open access
11
12
13
|
2022 |
Open access
6
6
7
|
2022 |
Open access
16
17
4
|
2021 |
Open access
16
13
10
|
2021 |
Open access
16
15
7
|
2021 |
Open access
22
20
4
|
2021 |
Open access
2
1
|
2020 |
11
10
5
|
2020 |
Open access
8
7
11
|
2020 |
Open access
51
46
4
|
2020 |
Open access
46
41
8
|
2020 |
Open access
24
20
3
|
2020 |
Open access
11
10
1
|
2019 |
Open access
3
3
|
2019 |
Open access
4
|
2019 |
Open access
26
23
5
|
2019 |
Open access
22
20
5
|
2019 |
Open access
19
19
5
|
2019 |
Open access
9
8
6
|
2018 |
Open access
33
30
2
|
2018 |
Open access
36
28
14
|
2018 |
Open access
15
14
4
|
2018 |
Open access
31
32
6
|
2017 |
23
21
1
|
2017 |
5
5
1
|
2017 |
Open access
6
6
1
|
2017 |
Open access
23
22
68
|
2017 |
40
35
1
|
2017 |
Open access
6
6
6
|
2017 |
Open access
26
26
3
|
2016 |
Open access
|
2016 |
7
6
|
2016 |
Open access
9
8
3
|
2016 |
Open access
34
35
|
2016 |
Open access
37
37
2
|
2016 |
10
10
|
2016 |
Open access
52
49
|
2016 |
Open access
16
16
461
|
2016 |
Open access
14
13
11
|
2016 |
Open access
43
43
1
|
2015 |
Open access
20
19
2
|
2015 |
Open access
30
28
|
2015 |
Open access
84
81
3
|
2015 |
Open access
16
15
4
|
2015 |
Open access
79
75
1
|
2015 |
Open access
29
27
40
|
2015 |
Open access
64
61
|
2014 |
Open access
22
21
|
2014 |
Open access
|
2014 |
Open access
90
82
|
2014 |
Open access
29
27
|
2013 |
5
5
|
2013 |
43
41
|
2013 |
46
45
|
2013 |
3
3
|
2012 |
Open access
20
21
|
2012 |
204
187
|
2012 |
Open access
|
2012 |
22
23
|
2011 |
10
10
|
2011 |
29
|
2011 |
Open access
27
27
|
2011 |
22
22
|
2011 |
Open access
188
174
|
2010 |
Open access
32
30
|
2010 |
Open access
12
10
|
2008 |
10
10
|
2008 |
76
|
2008 |
Open access
42
43
|
Research
Our expertise in blood vessels, and the endothelial cells which form their inner lining, allows us to critically interrogate diseases such as cancer, cardiovascular disease and diabetes. Our ultimate aim is to understand the fundamental biology of the blood vasculature so that new treatment opportunities for the most debilitating and deadly diseases can be produced to save thousands of lives every year, worldwide.
Research
Details | Registry | Status |
---|---|---|
Anti-fouling and/or anti-thrombotic medical devices Voelcker, Nicolas Hans; Moore, Eli; Bonder, Claudine Sharon |
AU | Filed |
Markers of endothelial progenitor cells and uses thereof Bonder, Claudine Sharon; Lopez, Angel Fransciso; Talbo, Gert Hoy |
AU | Granted |
Markers of endothelial progenitor cells and uses thereof Bonder, Claudine Sharon; López, Ángel Fransciso; Talbo, Gert Hoy |
EP | Filed |
Markers of endothelial progenitor cells and uses thereof Bonder, Claudine Sharon; Lopez, Angel Fransciso; Talbo, Gert Hoy |
US | Filed |
Markers of endothelial progenitor cells and uses thereof Bonder, Claudine Sharon; Lopez, Angel Fransciso; Talbo, Gert Hoy |
WO | Filed |
Medical devices using coated polymers Moore, Eli; Benveniste, Glen Leon; Bonder, Claudine Sharon |
WO | Filed |
Method of culturing cells Bonder, Claudine Sharon; Lopez, Angel Fransciso |
WO | Filed |
Novel cancer treatment involving modulation of il-3 activity Lopez, Angel F; Bonder, Claudine S; Thompson, Emma |
WO | Filed |
2020-present: Scientific advisor for Carina Biotech Ltd and previously TekCyte Pty Ltd (both start-up comapnies from CTM-CRC)
External engagement & recognition
Organisation | Country |
---|---|
Australian National University | AUSTRALIA |
Australian Research Council (ARC) | AUSTRALIA |
Baker Heart and Diabetes Institute | AUSTRALIA |
Beatson Institute | UNITED KINGDOM |
BreastScreen SA | AUSTRALIA |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Centre for Physical Activity in Ageing | AUSTRALIA |
Cornell University | UNITED STATES |
CSIRO Manufacturing Flagship | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
Garvan Institute of Medical Research | AUSTRALIA |
Garvan Medical Institute | AUSTRALIA |
German Cancer Research Center | GERMANY |
Griffith University | AUSTRALIA |
H. Lee Moffitt Cancer Center | UNITED STATES |
Hanson Centre for Cancer Research | AUSTRALIA |
Hanson Institute | AUSTRALIA |
Hebrew University | MEXICO |
Institute of Medical and Veterinary Science | AUSTRALIA |
La Trobe University | AUSTRALIA |
Lancaster University | UNITED KINGDOM |
Leibniz Institute for New Materials | GERMANY |
Lund University | SWEDEN |
Mayo Clinic | UNITED STATES |
Medical University of Graz | AUSTRIA |
Medical University of South Carolina | UNITED STATES |
Molecular Oncology Editorial Office | UNITED KINGDOM |
Monash University | AUSTRALIA |
Peter MacCallum Cancer Centre | AUSTRALIA |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
RMIT University | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Royal Brisbane and Women's Hospital | AUSTRALIA |
Royal College of Surgeons in Ireland | IRELAND |
Royal Eye & Ear Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Shanghai University | CHINA |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
St. Vincent's Institute of Medical Research | AUSTRALIA |
The Queen Elizabeth Hospital | AUSTRALIA |
Thomas Jefferson University | UNITED STATES |
Trinity College Dublin | IRELAND |
Tufts Medical Centre | UNITED STATES |
Universitat Freiburg im Breisgau | GERMANY |
University of Adelaide | AUSTRALIA |
University of Canberra | AUSTRALIA |
University of Illinois at Urbana-Champaign | UNITED STATES |
University of Melbourne | AUSTRALIA |
University of Nebraska Medical Center | UNITED STATES |
University of New South Wales | AUSTRALIA |
University of Oxford | UNITED KINGDOM |
University of Queensland | AUSTRALIA |
University of Sheffield | UNITED KINGDOM |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Tennessee | UNITED STATES |
University of Zurich | SWITZERLAND |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Washington University in St Louis | UNITED STATES |
Western Sydney University | AUSTRALIA |
Women's and Children's Health Network | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Medal of the Order of Australia (OAM)Governer General of the Commonwealth of Australia |
2025 |
AmbassadorBridging the Gap |
2019 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2018 |
AmbassadorBridging The Gap Foundation |
2017 |
MemberNorth American Vascular Biology Organisation (NAVBO) |
2017 |
MemberAustralasian Society for Immunology (ASI) |
2017 |
MemberAustralian and New Zealand Microcirculation Society (ANZMS) |
2017 |
MemberAustralian Society for Medical Research (ASMR) |
2017 |
MemberAmerican Association of Immunologists (AAI) |
2017 |
MemberAustralian Vascular Biology Society (AVBS) |
2017 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2017 |
Emerging Innovator AwardWinnovation Awards |
2016 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2016 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2015 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2014 |
Finalist, Peter Doherty Leading Light AwardAustralian Society for Medical Research (ASMR) |
2013 |
Project LeaderCell Therapy Manufacturing Co-operative Research Centre (CTM-CRC) |
2013 |
Project LeaderCo-operative Research Centre for Biomarker Translation (Biomarker CRC) |
2012 |
Project LeaderCo-operative Research Centre for Biomarker Translation (Biomarker CRC) |
2011 |
Project LeaderCo-operative Research Centre for Biomarker Translation (Biomarker CRC) |
2010 |
Invited media contact for Pankind the National Breast Cancer Foundation (NBCF), The Hospital Research Foundation (THRF), and the Centre for Cancer Biology.
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
110188-Enhancing therapy of acute myeloid leukaemia by predicting drivers of relapse | Current |
642 - Investigating causes of congenital heart and vascular defects | Current |
Advancing a novel biomarker for pancreatic cancer | Current |
Characterisation of extracellular matrix composition across the human brain and applications in brain organoid vascularisation | Current |
Deciphering how airway epithelial programming and inflammation cause chronic allergic airways disease | Current |
Enhancing cancer immunotherapy success by efficient recruitment of T cells to solid tumours | Current |
Interleukin-3 (IL-3) promotes blood vessel development in breast cancer | Current |
Investigating the origins and progression of pancreatic cancer | Current |
Molecular diagnosis for point-of-care skin cancer testing | Current |
Revealing the role of ICAM1 in breast cancer progression | Current |
Tumour protein D54 as a regulator of melanoma progression | Current |
Understanding how cancers modify the functional characteristics of the tumour extracellular matrix | Current |
Design and evaluation of blood-contacting coatings | Completed |
Desmoglein-2 as a regulator of pancreatic ductal adenocarcinoma progression | Completed |
Fundamental studies of poly(ethylene glycol-b-caprolactone) block copolymers self-assembly in water | Completed |
Peroxisome proliferator-activated receptor gamma interacts with sphingosine 1-phosphate to regulate vascular function | Completed |
Targeting sphingolipid metabolism in proteasome inhibitor-resistant multiple myeloma | Completed |
Targeting sphingosine kinase 1 to overcome venetoclax resistance in acute myeloid leukemia | Completed |
The role of flightless I in epidermal stem cell division, proliferation and differentiation during development, homeostasis, wound healing and epidermolysis bullosa-cutaneous squamous cell carcinoma | Completed |
The role of platelets in vasculogenic mimicry | Completed |
Transcriptional control of cellular identity in the lymphatic vasculature | Completed |
Using high throughput screening to design cell therapy scaffolds | Completed |
Vasculogenic mimicry: regulation and function in melanoma | Completed |